Vigil Neuroscience’s Post

Today on #WorldAlzheimersDay, C-Path honors those affected by Alzheimer’s and reaffirms our commitment to advancing research and drug development. Founded in 2008, the Critical Path for Alzheimer’s Disease is a global, neutral convener, bringing together diverse stakeholders across industry, regulatory agencies, and academia within a pre-competitive forum. By leveraging patient-level data contributions, CPAD enhances regulatory decision-making tools, addresses critical unmet needs, and accelerates therapeutic innovation to improve the lives of those living with Alzheimer’s and related dementias. We are also proud to share that Diane Stephenson, Executive Director of CPAD, will co-chair the “Advancing Regulatory Science to Deliver Precision Medicines” panel at the 2024 NIH Alzheimer’s Summit next week. This important discussion will bring together experts from the FDA to explore how regulatory science can help deliver precision treatments for Alzheimer’s patients. Learn more about CPAD, here: https://lnkd.in/gZjPjKin #CPath #WorldAlzheimersDay #AlzheimersResearch #CPAD #FDA #PrecisionMedicine #NIHSummit

Türkiye is becoming an attractive destination for clinical trials due to its robust healthcare infrastructure and a large pool of treatment-naive patients. In our latest video interview, CEO of Cromos Pharma, Vlad Bogin, MD, FACP, speaks with Seniz Sagol Tuysuz, the Country Head of Cromos Pharma in Türkiye. They explore why Türkiye is emerging as a biotech hub, discussing the clinical trial landscape, regulatory environment, quality and safety measures, patient recruitment, and best practices for successful trials. Discover why Türkiye should be considered for the next clinical research venture: https://lnkd.in/e6EgU7Gb #Podcast #Türkiye #CromosPharma

Türkiye is becoming an attractive destination for clinical trials due to its robust healthcare infrastructure and a large pool of treatment-naive patients. In our latest video interview, CEO of Cromos Pharma, Vlad Bogin, MD, FACP, speaks with Seniz Sagol Tuysuz, the Country Head of Cromos Pharma in Türkiye. They explore why Türkiye is emerging as a biotech hub, discussing the clinical trial landscape, regulatory environment, quality and safety measures, patient recruitment, and best practices for successful trials. Discover why Türkiye should be considered for the next clinical research venture: https://lnkd.in/edcWNWyk #Podcast #Türkiye #CromosPharma 

TRIAL NEWS 📣: The Partnership for Advancing Clinical Trials (PACT) consortium, in conjunction with the Tufts Center for the Study of Drug Development, has produced compelling results from a new study on the effectiveness of decentralized clinical trials (DCTs)🔬. In total, 13 clinical trial sponsors & CROs provided robust data on 60 clinical trials that deployed decentralized solutions. The analysis found that actual timelines beat planned timelines from first site activated to first patient enrolled, & from first patient to last patient enrolled ⏩. Early results of the PACT research also suggest that trials with DCT elements have more diverse study volunteers than those without, including a lower percentage of white participants, and higher percentage of Asian participants. Read more here: https://lnkd.in/eevNTkMW ________ Michelle Longmire, Pamela Tenaerts, MD, MBA, Tim Smith, Alison Holland, Jason Rothbart #clinicaltrials #clinicalresearch #healthcare #digitalhealth

The AMR Conference is just 4 weeks away 😊. Find out what the conference sessions will be about 👀 - today with “Meaningful clinical trials”: Designing clinical trials in #AMR is tricky. Many pitfalls are on the way and it is easy to miss the target, with the catastrophic consequences that one can imagine for the drug developer, especially when it is a small company. Are you ready to plan your next clinical adventure?  The session chaired by Glenn E Dale BioVersys AG will look into ways to implement meaningful clinical trials: David Paterson will highlight the difficulties in implementing a clinical trial in areas of high drug resistant infections Mark E. Jones PhD PMP will describe what made Basilea Pharmaceutica BSI study successful Ulrich Granzer will present how a global strategy for development should look like and some of the stumbling blocks Dr. Radu Botgros will comment on the expectations from a regulator’s (European Medicines Agency) point of view An unmissable discussion for all those who reach or are expected to reach clinical development! Interested? You can register here: https://lnkd.in/eVW8JWBe

Türkiye is becoming an attractive destination for clinical trials due to its robust healthcare infrastructure and a large pool of treatment-naive patients. In our latest video interview, CEO of Cromos Pharma, Vlad Bogin, MD, FACP, speaks with Seniz Sagol Tuysuz, the Country Head of Cromos Pharma in Türkiye. They explore why Türkiye is emerging as a biotech hub, discussing the clinical trial landscape, regulatory environment, quality and safety measures, patient recruitment, and best practices for successful trials. Discover why Türkiye should be considered for the next clinical research venture: https://lnkd.in/edcWNWyk #Podcast #Türkiye #CromosPharma

Check out this insightful interview with Vlad Bogin, MD, FACP and Seniz Sagol Tuysuz, Country Head in Türkiye, discussing why Türkiye is a top destination for clinical trials! 🌍🔬 Watch here: https://lnkd.in/e6yGt9UN

Human safety after administration of the new drug is the focus of Phase 1 clinical trials. Phase 1 clinical trial designs should answer key questions, including: https://lnkd.in/gpQ2z4UB #Phase1 #ClinicalTrial #ClinicalResearch

A clinical trial's effectiveness is highly dependent on the trial site's competence and resources and the Sponsor's level of support for the participating sites—Discover Minerva's expertise in overcoming clinical trial challenges. Our solutions redefine research excellence. Join us on the path to a healthier future. #MinervaResearchSolutions #regulatoryhurdles #TRIALTRIBULATIONS #crochallenges #TrialMonitoringIssues #qualitycontrolstruggles #MRS

Are you struggling with duplicate and professional research subjects? Look no further than Verified Clinical Trials ™ (VCT)! VCT is a cross-sponsor database that covers phase I-IV across multiple therapeutic indications globally. With VCT, you can save time and money while ensuring your clinical trial meets its endpoints. Contact VCT at connect@verifiedclinicaltrials.com to learn more! #duplicatesubjects #verifiedclinicaltrials #placebo